Core Viewpoint - CPI Card Group Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On August 8, 2025, CPI reported Q2 2025 financial results that missed both revenue and earnings estimates, with a GAAP earnings-per-share of $0.04, falling short by $0.46, and revenue of $129.75 million, missing estimates by $3.21 million [3]. - The company revised its 2025 outlook, now expecting net sales growth in the low double-digit to mid-teens range, an increase from the previous mid-to-high single-digit growth forecast [3]. Stock Market Reaction - Following the announcement of the financial results, CPI's stock price dropped by $5.37 per share, or 28.83%, closing at $13.25 per share on August 8, 2025 [4]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of CPI investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sensus Healthcare, Inc. and its officers or directors [1] Financial Performance - On August 7, 2025, Sensus reported a second quarter GAAP earnings-per-share of -$0.06, missing estimates by $0.09 [3] - The company's revenue for the second quarter was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million [3] - The revenue decline was primarily attributed to a lower number of units sold to a large customer, although there was some offset from growth in recurring revenue from Fair Deal Agreements [3] Stock Market Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Broadwind, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On August 12, 2025, Broadwind reported a GAAP loss per share of $0.04 for Q2 2025, which was $0.05 below consensus estimates [3]. - The company suspended its full-year 2025 financial guidance due to a definitive agreement to sell its industrial fabrication operations in Manitowoc, Wisconsin [3]. Stock Market Reaction - Following the announcement of the financial results, Broadwind's stock price decreased by $0.36, or 14.46%, closing at $2.13 per share on August 12, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. concerning allegations of securities fraud and unlawful business practices [1][2] Group 1: Lawsuit Details - The class action lawsuit involves claims that SelectQuote and its officers engaged in securities fraud or other unlawful business practices [2] - Investors have until October 10, 2025, to request to be appointed as Lead Plaintiff if they purchased SelectQuote securities during the Class Period [2] Group 2: Allegations by the DOJ - On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging the company received "tens of millions of dollars" in illegal kickbacks from health insurance companies from 2016 to at least 2021 [4] - The DOJ claims SelectQuote conspired with major insurers to discriminate against less profitable beneficiaries, including those with disabilities [4] - SelectQuote allegedly made materially false claims about offering "unbiased coverage comparisons," directing Medicare beneficiaries to plans that paid them the most money [4] - Following the DOJ's announcement, SelectQuote's stock price fell by $0.61 per share, or 19.24%, closing at $2.56 per share on May 1, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices by Encompass Health Corporation and its officers or directors [1] Group 1: Allegations and Impact - A New York Times article published on July 15, 2025, alleged that Encompass's for-profit hospitals perform below average on key safety measures, including having statistically significantly worse rates of potentially preventable readmissions at 34 facilities [3] - The article highlighted alarming mistakes that led to patient fatalities in Encompass-owned facilities [3] - Following the publication of the article, Encompass's stock price dropped by $12.39 per share, or 10.35%, closing at $107.28 per share on the same day [4] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [5]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation regarding potential securities fraud or unlawful business practices by the company and its officers [1][3] - Neogen's fourth quarter fiscal 2025 results indicated a decline in EBITDA margin to the high-teens percentage, down from 22% in the previous quarter, attributed to elevated inventory write-offs [3] Company Performance - Neogen's stock price experienced a significant drop of $1.04 per share, or 17.3%, closing at $4.96 per share following the announcement of its financial results [3] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Designer Brands Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - On June 10, 2025, Designer Brands announced the withdrawal of its 2025 guidance due to a soft start to the year, an unpredictable macro environment, and deteriorating consumer sentiment [3] - Following the announcement, Designer Brands' stock price fell by $0.68 per share, or 18.23%, closing at $3.05 per share on the same day [3] Group 2 - Designer Brands is focusing on amplifying value in retail channels, preserving margins, controlling costs, and mitigating tariff impacts in response to market volatility [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by The J.M. Smucker Company and its officers/directors, following disappointing financial results and significant impairment charges related to the acquisition of Hostess Brands [1][3]. Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3]. - For Q3 2025, Smucker reported a comparable net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3]. - In Q4 2025, the company experienced a further 14% decrease in comparable net sales in the Sweet Baked Snacks segment, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [3]. - Following these announcements, Smucker's stock price dropped by $17.44 per share, or 15.59%, closing at $94.41 per share on June 10, 2025 [3]. Strategic Outlook - The company has revised its 2026 financial plan, indicating decreased net sales in the Sweet Baked Snacks segment due to sustained underperformance since the acquisition, contradicting earlier assurances of synergies driving growth [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Charter Communications and its officers or directors, following a significant decline in customer numbers and a sharp drop in stock price [1][3]. Financial Performance - Charter Communications reported a decline of 117,000 total internet customers in Q2 2025, compared to a decline of about 100,000 in Q2 2024, after adjusting for the impact of the Affordable Connectivity Program [3]. - The company also experienced a decrease of 80,000 total video customers during the same period [3]. - Following the release of these financial results, Charter's stock price fell by $70.25, or 18.5%, closing at $309.75 per share on July 25, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving NeoGenomics and its officers or directors, following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - NeoGenomics reported second-quarter 2025 revenue of $181.3 million, which was below consensus estimates [3]. - The company experienced a net loss of $45.1 million during the same period [3]. - NeoGenomics revised its 2025 revenue forecast down to a range of $720 million to $726 million, a decrease from the previous estimate of approximately $753 million [3]. - The adjusted EBITDA projection was also lowered to a range of $41 million to $44 million, down from a prior range of $55 million to $58 million [3]. Stock Market Reaction - Following the release of the financial results, NeoGenomics' stock price fell by $1.21 per share, or 18.73%, closing at $5.25 per share on July 29, 2025 [4].